S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Forecast, Price & News

$0.75
+0.06 (+8.70%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.70
$0.75
50-Day Range
$0.50
$0.90
52-Week Range
$0.45
$3.74
Volume
96,111 shs
Average Volume
178,040 shs
Market Capitalization
$74.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Accelerate Diagnostics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$123,024 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.59) to ($0.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

834th out of 983 stocks

Analytical Instruments Industry

21st out of 27 stocks


AXDX stock logo

About Accelerate Diagnostics (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Craig-Hallum Keeps Their Hold Rating on Accelerate Diagnostics (AXDX)
Accelerate Diagnostics (AXDX) to Release Earnings on Wednesday
See More Headlines

AXDX Price History

AXDX Company Calendar

Last Earnings
3/29/2023
Today
6/03/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXDX
Employees
220
Year Founded
N/A

Profitability

Net Income
$-62,490,000.00
Net Margins
-516.49%
Pretax Margin
-522.81%

Debt

Sales & Book Value

Annual Sales
$12.75 million
Book Value
($0.39) per share

Miscellaneous

Free Float
57,703,000
Market Cap
$74.87 million
Optionable
Optionable
Beta
1.19

Key Executives

  • Jack PhillipsJack Phillips
    President, Chief Executive Officer & Director
  • Maya Gowri
    Head-Operations & Senior Vice President
  • David Patience
    Chief Financial Officer
  • Lawrence Mertz
    Chief Technology Officer
  • Gretchen Strohminger
    Senior VP, Head-Human Resources & Culture













AXDX Stock - Frequently Asked Questions

Should I buy or sell Accelerate Diagnostics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXDX shares.
View AXDX analyst ratings
or view top-rated stocks.

How have AXDX shares performed in 2023?

Accelerate Diagnostics' stock was trading at $0.7060 at the beginning of 2023. Since then, AXDX shares have increased by 6.2% and is now trading at $0.75.
View the best growth stocks for 2023 here
.

When is Accelerate Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our AXDX earnings forecast
.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Wednesday, March, 29th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The medical research company had revenue of $2.97 million for the quarter, compared to analysts' expectations of $3 million.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Griffin Asset Management Inc. (10.29%), Tejara Capital Ltd (0.36%), Allworth Financial LP (0.15%), TCI Wealth Advisors Inc. (0.09%), Chartist Inc. CA (0.07%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends
.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $0.75.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $74.87 million and generates $12.75 million in revenue each year. The medical research company earns $-62,490,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

The company employs 220 workers across the globe.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580.

This page (NASDAQ:AXDX) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -